

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization International Bureau



(43) International Publication Date
21 April 2005 (21.04.2005)

PCT

(10) International Publication Number
WO 2005/035731 A2

(51) International Patent Classification⁷: C12N (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(21) International Application Number: PCT/US2004/033530

(22) International Filing Date: 8 October 2004 (08.10.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/510,250 9 October 2003 (09.10.2003) US
60/555,797 23 March 2004 (23.03.2004) US

(71) Applicant (for all designated States except US): INVERSEON, INC. [US/US]; Suite 102, 1701 Jackson Street, San Francisco, CA 94109 (US).

(72) Inventor; and

(75) Inventor/Applicant (for US only): BOND, Richard, A. [US/US]; 3509-D Bradford, Houston, TX 77025 (US).

(74) Agent: FARBER, Michael, B.; Catalyst Law Group, APC, Suite 220, 4330 La Jolla Village Drive, San Diego, CA 92122 (US).

Published:
— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 2005/035731 A2

(54) Title: METHODS FOR TREATING DISEASES AND CONDITIONS WITH INVERSE AGONISTS AND FOR SCREENING FOR AGENTS ACTING AS INVERSE AGONISTS

(57) Abstract: The present invention describes a method for treating a disease or condition associated with the activity of a G protein coupled receptor (GPCR) comprising administering an inverse agonist for the GPCR, alone or in combination with an agonist for the GPCR, to an organism with a disease or condition associated with the activity of the GPCR in a quantity and for a period that causes an increase in the population of spontaneously active GPCRs associated with that physiological function, thereby producing a therapeutic effect to ameliorate the disease or condition. This provides a basis for so-called "paradoxical pharmacology." These methods can be used to treat pulmonary airway diseases, including asthma and chronic allergic rhinitis, among other diseases and conditions, including obesity. The present invention further describes a screening method for screening a compound for inverse agonist activity to a GPCR.